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Abstract 45 
Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to 46 
chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the 47 
mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a 48 
central role within mitochondrial antioxidant pathways, protecting cells from oxidative stress. 49 
Inactivating human NNT mutations result in congenital adrenal insufficiency. We hypothesized 50 
NNT silencing in ACC cells will induce toxic levels of oxidative stress. To explore this, we 51 
transiently knocked down NNT in NCI-H295R ACC cells. As predicted, this manipulation 52 
increased intracellular levels of oxidative stress; this resulted in a pronounced suppression of cell 53 
proliferation and higher apoptotic rates, as well as sensitization of cells to chemically-induced 54 
oxidative stress. Steroidogenesis was paradoxically stimulated by NNT loss, as demonstrated by 55 
mass spectrometry-based steroid profiling. Next, we generated a stable NNT knockdown model in 56 
the same cell line to investigate the longer-lasting effects of NNT silencing. After long-term 57 
culture, cells adapted metabolically to chronic NNT knockdown, restoring their redox balance and 58 
resilience to oxidative stress, although their proliferation remained suppressed. This was associated 59 
with higher rates of oxygen consumption. The molecular pathways underpinning these responses 60 
were explored in detail by RNA sequencing and non-targeted metabolome analysis, revealing 61 
major alterations in nucleotide synthesis, protein folding and polyamine metabolism.  Our study 62 
provides the first pre-clinical evidence of the therapeutic merit of antioxidant targeting in ACC as 63 
well as illuminating the long-term adaptive response of cells to oxidative stress.   64 
 4 
Introduction 65 
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy. The majority of 66 
patients present with, or eventually develop, metastatic disease, which shows limited or no 67 
responsiveness to cytotoxic chemotherapy (1, 2). A recent randomized trial revealed a median 68 
survival of <15 months for patients with disseminated disease receiving combination 69 
chemotherapy (3). Glucocorticoid or androgen excess often constitutes an additional clinical 70 
burden on ACC patients, undermining their quality of life (1).  Unfortunately, the obvious need 71 
for more effective medical treatment options in ACC patients remains unmet, despite the 72 
remarkable progress in our understanding of the molecular biology of ACC in the last two decades 73 
(1). 74 
Recent genetic studies have provided new insights into adrenal pathophysiology, revealing 75 
that inactivating mutations in the gene encoding the antioxidant enzyme Nicotinamide Nucleotide 76 
Transhydrogenase (NNT) underlie a rare, hereditary form of primary adrenal insufficiency  (4). 77 
Affected patients present in early childhood with failure to thrive, hypotension and hypoglycemia, 78 
due to inability of the adrenal glands to produce sufficient cortisol (4). Intriguingly, despite the 79 
key role of NNT in preserving cellular redox balance and its ubiquitous expression, the adrenal 80 
glands are the only affected organ in most patients; this observation suggests a selective sensitivity 81 
of the adrenal glands to NNT loss (4, 5). Supportive of this, NNT-deficient mice harbor adrenal 82 
glands with disorganized cortical architecture and high apoptotic rates in their adrenal zona 83 
fasciculata, the location of glucocorticoid synthesis, but no other abnormality (4).  84 
NNT is a dimeric proton pump that resides in the inner mitochondrial membrane of 85 
eukaryotic cells and uses the transmembrane proton gradient to catalyze the transfer of reducing 86 
equivalents from NADH to NADP+, according to the reaction 87 
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NADH + NADP++ H+Intermembrane  ↔  NAD+ + NADPH + H+matrix (6, 7) 88 
NADPH is an essential donor of reducing power to the two main mitochondrial antioxidant 89 
pathways, the glutathione and the thioredoxin pathways, which protect the mitochondria from the 90 
deleterious effects of oxidative stress with their capacity to detoxify reactive oxygen species (e.g. 91 
hydrogen peroxide, H2O2). Reactive oxygen species (ROS), the molecular mediators of oxidative 92 
stress, are continuously produced within the mitochondria by electron leakage along the respiratory 93 
chain complexes and the tricarboxylic acid cycle (TCA); in adrenocortical mitochondria, 94 
steroidogenesis represents an important additional source of ROS (8-11). Excessive levels of 95 
oxidative stress lead to irreversible DNA, protein and lipid damage, which can culminate in 96 
apoptotic cell death (Fig. 1A) (12). 97 
Drawing on these data, which indicate a distinct metabolic vulnerability of the adrenal 98 
cortex to oxidative stress, we explored the value of antioxidant targeting as a novel therapeutic 99 
approach in ACC, focusing on NNT as a putative treatment target. Interrogating a publicly 100 
available whole genome gene expression database (13), we observed that NNT is up-regulated in 101 
ACCs in comparison to benign adrenocortical adenomas and healthy adrenals (Fig. 1B).  102 
Therefore, we hypothesized NNT silencing in ACC cells will impair their antioxidant capacity and 103 
lead to progressive accumulation of ROS, inducing unsustainable oxidative toxicity within the 104 
mitochondria and eventually triggering cellular apoptosis. We also postulated that steroidogenesis 105 
will be suppressed as a result of NADPH depletion and/ or increased oxidative stress.    106 
 6 
Materials and Methods 107 
Cell culture protocol and cell line validation 108 
NCI-H295R (RRID:CVCL_0458) ACC cells (passage 10-25) were cultured under 109 
standard conditions using DMEM/Ham’s F-12 medium (Gibco, Thermo Fisher) supplemented 110 
with 2.5% Nu serum (Corning), 1% penicillin-streptomycin (Gibco, Thermo Fisher) and 1% ITS+ 111 
universal cell culture premix (Corning). Cell line identity was confirmed through Short Tandem 112 
Repeat (STR) genetic analysis performed by the DNA Diagnostics Company (London, UK) 113 
followed by comparison to genetic profiles provided by the American Tissue Culture Collection 114 
(ATCC) (http://www.lgcstandards-atcc.org) (Suppl. Table 1). 115 
Small-interfering RNA (siRNA) transfection 116 
  Transient NNT gene silencing was achieved through transfection of NCI-H295R cells with 117 
small interfering RNA (siRNA), using Viromer Blue (Lipocalyx) molecules as transfection 118 
vehicles.  Three alternative siRNAs targeting different areas of the NNT gene were tried (Life 119 
Technologies, HSS118900, HSS118901 and HSS118902), and the one exhibiting the most 120 
consistent efficiency in knocking down NNT (HSS118902) was selected for subsequent 121 
experiments.  HSS118901 was used to corroborate results in proliferation and apoptosis assays, 122 
whose results are open to confounding by off-target effects. A scrambled, non-sense siRNA 123 
(Silencer Select 1 negative control, Life Technologies) was used as negative control (SCR siRNA). 124 
Viromer-siRNA transfection was performed according to the manufacturer’s instructions in 6-well 125 
plates (300,000 cells/well) and 96-well plates (6-8,000 cells/well).  126 
Short-hairpin RNA (shRNA) transfection 127 
Lentiviral vectors were obtained from Dharmacon (UK) in a p.GIPZ backbone and contained 128 
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5 shRNAs specific for human NNT (RHS4430-98851990; RHS4430-98913600; RHS4430-129 
98524425; RHS4430-101033169; RHS4430-101025114) under the control of the CMV promoter, 130 
as well as the puromycin resistance and green fluorescence protein (GFP) genes. Vectors 131 
expressing non-sense, scrambled shRNA (SCR shRNA) were used as negative controls. HEK293T 132 
cells (packaging cells, RRID:CVCL_0063) were transfected with the shRNA particles by 133 
lipofectamine transfection (Thermo Fisher), according to the manufacturer’s instructions.  Cell 134 
media containing the viral particles was collected 48-72 h post-transfection and used to transduce 135 
NCI-H295R cells. Four days after transfection, GFP-positive cells were selected in 4μg/ml 136 
puromycin. Transduction efficiency was determined by fluorescence microscopy and Western 137 
Blotting for NNT expression.  138 
Gene expression  139 
Gene expression for NNT and steroidogenic enzymes was evaluated at a transcriptional level 140 
by quantitative real-time polymerase chain reaction (qRT-PCR). RNA extraction was performed 141 
using the RNeasy Mini kit (Qiagen) following the manufacturer’s instructions. Reverse 142 
transcription to generate complementary DNA (cDNA) was carried out using the TetrocDNA 143 
Synthesis Kit (Bioline), following the manufacturer’s instructions (500 – 2,000 ng of RNA per 144 
reaction used).  cDNA concentration was determined by use of a fluorescent DNA dye (Quant-145 
iT™ PicoGreen® dsDNA reagent, Thermo Fisher), comparing sample fluorescence to the 146 
fluorescence exhibited by a dilution series of samples of known concentrations (Wallac Victor 147 
1420 multilabel counter). Gene expression was then quantified by qRT-PCR, using the Taqman 148 
Gene Expression System (Thermo Fisher). Reactions were run in a 7500 ABI qRT-PCR analyzer 149 
[50oC incubation for 2 minutes, 95oC for 10 minutes, followed by 40 cycles of 95oC for 15 seconds 150 
(denaturation) then 60oC for 1 minute (annealing-extension)]. All reactions were normalized 151 
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against the housekeeping gene RPLPO (large ribosomal protein). Data are expressed as ΔCt values 152 
[ΔCt=(Ct of the target gene) – (Ct of the housekeeping gene)] or fold-change to control cells (2-153 
ΔΔCt), where ΔΔCt = ΔCt (NNT knockdown cells) – ΔCt (control cells). 154 
Protein expression  155 
Protein lysate generation was performed by applying RIPA buffer (Sigma-Aldrich) with 156 
protease inhibitor cocktail (Sigma-Aldrich) to adherent cells grown in 6-well plates and subsequent 157 
collection by scraping. Total protein concentration was estimated colorimetrically using the BCA 158 
Protein Assay Kit (Thermo Fisher) as per the manufacturer’s instructions, measuring absorbance 159 
at 560 nm (Wallac Victor 1420 multilabel counter). NNT protein expression level was assessed by 160 
Western Blotting. Samples were run in 10% SDS-PAGE (polyacrylamide) Gels (Thermo Fisher) 161 
and transferred to a nitrocellulose membrane using the iBLOTTM Dry Transfer System (Thermo 162 
Fisher). Membranes were subsequently probed with anti-NNT antibody produced in rabbit 163 
(HPA004829, Sigma-Aldrich, RRID:AB_1079495) at a 1:500 dilution and secondary anti-rabbit 164 
antibody (sc-2030, Santa-Cruz, USA, RRID:AB_631747) at a 1:2,000 dilution. -actin was used 165 
as control protein (primary antibody A5441, RRID:AB_476744  from Sigma-Aldrich and 166 
secondary anti-mouse antibody from Santa-Cruz (sc-2005, RRID:AB_631736), dilutions 1:10,000 167 
and 1:20,000, respectively).  168 
Reduced to oxidized glutathione ratio (GSH/GSSG)  169 
Total cell glutathione (GSH + GSSG) and oxidized glutathione (GSSG) were measured by 170 
luminescence in cells growing in opaque-walled 96-well plates, using the GSH/GSSG-Glo Assay 171 
(Promega) according to the manufacturer’s instructions. The resulting luminescent signal was 172 
measured in Wallac Victor 1420 multi-label counter, using triplicate samples per treatment group 173 
and subtracting blank measurements to produce net results. GSH/GSSG ratios were calculated 174 
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directly from Net Relative Luminescence Units (RLU) measurements using the equation 175 
GSH/GSSG ratio = [Net total glutathione RLU-Net GSSG RLU]/ [Net GSSG RLU/2].  176 
Metabolic Flux Analysis (Seahorse XF) 177 
Metabolic Flux analysis in a Seahorse XF 24 Analyzer was used to assess the effect of 178 
NNT knockdown on mitochondrial bioenergetics, applying the Seahorse XF Cell Mito Stress kit. 179 
Cells were plated in Seahorse XF microplates the day before the experiment at a density of 100,000 180 
cells/ well. Changes in oxygen concentration provide the oxygen consumption rate (OCR), which 181 
is a measure of mitochondrial respiration. Changes in proton concentration (or pH) provide the 182 
extracellular acidification rate (ECAR), reflective of the rate of glycolysis. Measurements were 183 
taken at baseline and after successive application of compounds interfering with oxidative 184 
phosphorylation: oligomycin (complex V inhibitor, 2 μM), Carbonyl cyanide-p-185 
trifluoromethoxyphenylhydrazone (FCCP, mitochondrial uncoupler, 1 μΜ) and Antimycin A + 186 
Rotenone (Complex I and III inhibition, 1 μΜ). Results were normalized to protein concentration, 187 
measured by the BCA Protein Assay Kit (Thermo Fisher). 188 
Cell proliferation and apoptosis 189 
Cell proliferation was assessed in 96-well plates (loading concentration 6-8,000 cells/well), 190 
using the CyQuant Proliferation Assay Kit (Thermo Fisher) and following the manufacturer’s 191 
instructions. Cell DNA fluorescence was measured at the end of the time course, i.e. 166 hours 192 
post siRNA transfection and/ or 96 hours after treatment. The beginning of treatment was used as 193 
the baseline time point (t=0) for each proliferation series; for siRNA knockdown experiments, 72 194 
hours post transfection was taken as the baseline time point. Proliferation rates were provided by 195 
the following ratio: [(end cell number– baseline cell number)]/ baseline cell number. 196 
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Cellular apoptosis was assessed using the Caspase-Glo 3/7 Assay kit (Promega), a 197 
luminescence-based assay measuring Caspase 3 and 7 activity in cell lysates, and following the 198 
manufacturer’s instructions.  Luminescent signals were quantified using the Wallac Victor 1420 199 
multilabel counter.  At the end of the assay, media and reagents were removed from all wells and 200 
stored at -80oC. The next day, relative quantification of cell number was performed by use of the 201 
CyQuant® Proliferation Assay Kit, as described above. Luminescence values obtained in the 202 
caspase assay were normalized to the fluorescence results of the proliferation assay. 203 
            Paraquat and auranofin were purchased from Sigma-Aldrich (UK). Buthionine sulfoximine 204 
(BSO) was purchased from Cayman Chemical (USA). 205 
In vitro steroid profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 206 
Steroid synthesis by NCI-H295R cells was assessed by comprehensive multi-steroid 207 
profiling employing liquid chromatography-tandem mass spectrometry (LC-MS/MS), as 208 
described previously (14, 15). Steroid extraction and analysis by LC-MS/MS are discussed in 209 
Supplementary Methods. 210 
RNA sequencing  211 
RNA was prepared in triplicate from NCI-H295R KD siRNA, SCR siRNA (72 hours post-212 
transfection), KD shRNA and SCR shRNA cells using the RNeasy Mini kit (Qiagen). Libraries 213 
were generated using the TruSeq Stranded mRNA Library Prep Kit (Illumina, USA). 4 nM library 214 
(containing the 16 pooled libraries) was sequenced on a NextSeq500 System (Illumina). Pathway 215 
analysis on sequencing data was completed using GAGE V2.22 package from Bioconductor 216 
release 3.2 and referencing the KEGG pathways. Differentially expressed genes were considered 217 
significant applying a false discovery rate of <5% (q<0.05).   Differentially regulated pathways 218 
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were called at a p value of <0.01. A detailed description of the methodology for RNA sequencing 219 
and pathway analysis can be found in Supplementary Methods.  220 
In addition, RNA sequencing data from recently published work on three different mouse 221 
strains (Nnt inactivating mutation, C57BL/6J (RRID:MGI:3702942) ; wild-type, C57BL/6NHsd 222 
(RRID:MGI:2161078)  ; and transgenic Nnt overexpressor, C57BL/6JBAC) (16) were re-analyzed 223 
employing the same pathway analysis as for the human cell-based model; detailed information on 224 
this dataset can be found in Supplementary Methods. 225 
Metabolome analysis 226 
Cell and media samples were prepared for non-targeted metabolome analysis through 227 
quenching cell metabolism with a mix of acetonitrile, methanol and water (Sigma-Aldrich). The 228 
process of sample generation and analysis is described in more detail in the Supplementary 229 
Methods. 230 
Statistical analysis 231 
Statistical analysis was performed using GraphPad Prism 7 Software 232 
(RRID:SCR_002798). Data are represented as mean  SEM values, unless otherwise stated. 233 
Comparisons were made using Student’s paired t-test for normally distributed data or Wilcoxon’s 234 
signed-rank test for data not following a Gaussian distribution. Multiple comparisons (BSO and 235 
auranofin treatments) were performed by one-way ANOVA followed by post-hoc multiple 236 
comparison testing. Statistical methods for the RNA sequencing and untargeted metabolome 237 
analysis are detailed in Supplementary Methods.  238 
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Results 239 
Transient and stable NNT knockdown 240 
Transient NNT silencing by siRNA knockdown was employed to explore the acute effects 241 
of NNT loss on ACC cells. NNT siRNA transfection in NCI-H295R cells yielded efficient gene 242 
silencing for at least 166 hours post-transfection with two different siRNAs (Suppl. Fig. 1A-B). 243 
All subsequent experiments were performed with the siRNA that gave the best knockdown results 244 
on real-time PCR and Western Botting (referred to here as KD siRNA). The second siRNA (KD 245 
siRNA2) was used to corroborate the results of proliferation and apoptosis assays, whose results 246 
are most likely to be distorted by off-targets effects.    247 
Stable NNT silencing by shRNA knockdown was used to delineate the long-term effects 248 
of NNT loss on ACC cells. Stable NNT knockdown in NCI-H295R cells was achieved by lentiviral 249 
transfection with shRNA-expressing plasmids and selection with puromycin, and resulted in 250 
permanent NNT silencing (Suppl. Fig. 1C-D).  251 
 NNT siRNA knockdown increases cellular oxidative stress  252 
Given the central role of NNT within the mitochondrial ROS scavenging network, we 253 
hypothesized that NNT knockdown will increase oxidative stress in NCI-H295R cells. To test this, 254 
we measured the intracellular ratio of reduced to oxidized glutathione (GSH/GSSG), an established 255 
marker of oxidative stress; a decrease in the GSH/GSSG ratio indicates that the proportion of 256 
oxidized intracellular glutathione is increased as a result of higher intracellular ROS levels. Indeed, 257 
we observed a statistically significant (p<0.05) decrease in the GSH/GSSG ratio in NNT KD 258 
siRNA-transfected cells 96 hours post-transfection (Fig. 2A).  259 
NNT siRNA knockdown suppresses cell proliferation and induces apoptotic cell death 260 
 13 
Cell proliferation rates were assessed over the time window from 72 to 166 hours post-261 
transfection, a period with consistent NNT knockdown confirmed at protein level (Suppl. Fig. 1). 262 
NNT knockdown by KD siRNA transfection led to a marked decrease in cellular proliferation rates 263 
(Fig. 2B). These results were corroborated by use of a second siRNA against NNT, which 264 
completely obliterated cell proliferation (Suppl. Fig. 2). 265 
To establish whether the increased oxidative stress observed with NNT KD leads to higher 266 
rates of apoptosis - as predicted by ROS physiology- we measured intracellular caspase 3 and 7 267 
activity 120 hours post-transfection. We also quantified relative cell numbers by DNA 268 
fluorescence at the same time-point to standardize results to cell number. NNT KD siRNA cells 269 
exhibited significantly higher caspase 3/7 activity than SCR siRNA cells (p<0.05), confirming our 270 
hypothesis that NNT knockdown triggers cell death by apoptosis (Fig. 2C). The effect was even 271 
more marked with the alternative siRNA against NNT (Suppl. Fig. 2). 272 
 NNT siRNA knockdown sensitizes cells to oxidative stress 273 
Next, we evaluated changes in mitochondrial respiration by direct measurement of the 274 
cellular oxygen consumption rate (OCR), using Extracellular Flux analysis. Despite the location 275 
of NNT in the inner mitochondrial membrane, we observed no statistically significant difference 276 
between NNT KD siRNA- and SCR siRNA-transfected cells, either at baseline or in response to 277 
mitochondrial respiration disruptors (Fig. 2D). Baseline extracellular acidification rate (ECAR), 278 
representative of the glycolytic rate, was also similar between the two groups (Fig. 2E). 279 
Considering the integral role of NNT in mitochondrial antioxidant defense and the 280 
detrimental impact of NNT inhibition on redox balance, we further hypothesized that NNT loss 281 
will render NCI-H295R cells more sensitive to chemically induced oxidative stress. To assess this 282 
assumption, we treated NCI-H295R cells with a sub-toxic dose of paraquat, a pesticide which 283 
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induces oxidative stress in vitro generating superoxide. Treatment with 10 μM of paraquat for 96 284 
hours led to a statistically significant decrease in cell proliferation in cells transfected with KD 285 
siRNA, but not in their counterparts that had been transfected with SCR siRNA (Fig. 2F).  286 
Redox adaptation develops with stable NNT knockdown 287 
To explore the long-term metabolic consequences of NNT silencing in NCI-H295R cells, 288 
we employed a different model, involving stable transfection with shRNA against NNT. With 289 
long-term culture under persistent NNT silencing (4-12 weeks post-transfection), cells managed 290 
to restore their redox balance to the levels of their SCR shRNA-transfected counterparts (Fig. 3A).  291 
ACC proliferation remains suppressed with stable NNT knockdown 292 
The distinct metabolic consequences of NNT silencing in the stable knockdown setting, in 293 
comparison to acute knockdown by NNT siRNA, translated into an attenuated response with 294 
respect to cellular proliferation and viability. Proliferation rates remained significantly lower in 295 
KD shRNA-transfected cells compared to the SCR shRNA-transfected controls; however, this was 296 
less pronounced than the decrease in proliferation we observed with siRNA-mediated knockdown 297 
(Fig. 3B). Apoptotic rates did not differ between SCR shRNA and KD shRNA cells (Fig. 3C), in 298 
keeping with the restoration of redox homeostasis we had ascertained based on the reduced/ 299 
oxidized glutathione ratio.  300 
Interestingly, NNT KD shRNA cells consumed more oxygen than SCR shRNA cells at 301 
baseline (Fig. 3D). This finding potentially reflects higher energy needs in NNT deficient cells. 302 
The same trend was observed in ECAR, a surrogate marker of glycolysis, but without reaching 303 
statistical significance (Fig. 3E). Finally, stable NNT knockdown did not enhance cell sensitivity 304 
to oxidative stress induced by paraquat. (Fig. 3F). 305 
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Transient, but not stable, NNT knockdown paradoxically stimulates steroidogenesis 306 
The effects of NNT silencing on steroidogenesis were evaluated by comprehensive multi-307 
steroid profiling in cell media by LC-MS/MS, as well as gene expression analysis by qRT-PCR. 308 
We postulated that NNT silencing will disrupt steroidogenesis, either depriving mitochondrial 309 
steroidogenic monooxygenases [cholesterol side-chain cleaving enzyme (CYP11A1), 11-310 
hydroxylase (CYP11B1), aldosterone synthase (CYP11B2)] of their essential electron donor 311 
NADPH, or due to oxidative stress-induced down-regulation of key steroidogenic enzymes. 312 
Surprisingly, NNT KD siRNA-transfected cells actually produced significantly more 313 
glucocorticoids (cortisol) and androgens (androstenedione) than controls (Fig. 4A-B). Individual 314 
enzyme activities were determined as product-to-substrate ratios for three key steroidogenic 315 
enzymes, 11-hydroxylase (CYP11B1), 21-hydroxylase (CY21A2), and CYP17A1 17/20-lyase 316 
activity; all three displayed higher activity in NNT KD siRNA-transfected cells, in keeping with a 317 
paradoxical generalized stimulation of steroidogenesis by acute NNT loss (Fig. 4C-E).  318 
By contrast, in the shRNA-transfected cells with chronic NNT silencing we observed no 319 
significant impact on steroidogenesis, with similar rates of cortisol or androstenedione synthesis 320 
between KD shRNA and SCR shRNA cells (Fig. 4A-E).  321 
We also explored the gene expression alterations underpinning the enhanced steroid 322 
production of cells transfected with KD siRNA, comparing the expression of core steroidogenic 323 
genes (StAR, CYP11A1, CYP21A2, CYP17A1, 3βHSD2) between KD siRNA and SCR siRNA 324 
cells by qRT-PCR. There was a statistically significant increase in the expression of cytochrome 325 
P450 (CYP) type 2 steroidogenic enzymes located in the ER CYP21A2 (p<0.05), CYP17A1 326 
(p<0.05), as well as the ER dehydrogenase HSD3B2 (p<0.01) in NNT KD siRNA cells (Suppl. 327 
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Table 2). CYP11B1 and CYP11B2 expression levels were too low to be quantified by qRT-PCR 328 
in our cells. 329 
Analysis of gene expression by RNA sequencing in an extended panel of 14 steroidogenic 330 
genes indicated a significant up-regulation of CYP21A2 (q<0.05) and CYP17A1 (q<0.01), as well 331 
as the ACTH receptor MC2R (q<0.01) in the transient NNT knockdown model; no significant 332 
changes were observed in the stable knockdown model (Fig. 4F).   333 
NCI-H295R cells are sensitive to glutathione depletion and thioredoxin reductase inhibition 334 
Given the effects of NNT inhibition on NCI-H295R cell proliferation, we went on to 335 
evaluate the sensitivity of ACC cells to isolated inhibition of each of the two pillars of 336 
mitochondrial antioxidant defense: the glutathione pathway and the thioredoxin pathway.  337 
We used buthionine sulfoximine (BSO), a potent inhibitor of the glutathione-producing 338 
enzyme c-glutamylcysteine ligase, to deplete intracellular glutathione. We observed a decline in 339 
cell proliferation with a BSO dose of  100 M after 96 hours of treatment (Fig. 5A).   340 
Pharmacological manipulation of the alternative mitochondrial antioxidant pathway, the 341 
thioredoxin pathway, was achieved by auranofin, a gold complex agent with a well-established 342 
capacity to inhibit thioredoxin reductase.  NCI-H295R treatment with doses of  1 M was 343 
associated with major cytotoxity (Fig. 5B).  344 
Finally, dual inhibition of the glutathione and thioredoxin pathways by co-administration 345 
of low-dose BSO (50 M) and auranofin (0.2 M) resulted in marked cytotoxicity, suggesting that 346 
a potent synergistic effect can be achieved by dual pathway targeting (Fig. 5C). 347 
Whole transcriptome and metabolome analyses reveal extensive metabolic perturbations with 348 
transient NNT knockdown, as well as changes in protein processing and polyamine metabolism 349 
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with stable NNT knockdown  350 
In order to uncover the molecular mechanisms that underpin the effects we observed in the 351 
two models and the discrepancies between them, we applied whole transcriptome analysis in RNA 352 
extracted from four groups of NCI-H295R cells (NNT KD siRNA vs SCR siRNA, NNT KD 353 
shRNA vs SCR shRNA). 842 genes were differentially regulated between NNT KD siRNA and 354 
SCR siRNA cells; 247 genes were differentially regulated between NNT KD shRNA and SCR 355 
shRNA cells (q<0.05). Of note, only 17 of the genes regulated differentially between KD and SCR 356 
cells were identical in the two models, NNT KD siRNA and shRNA (Suppl. Table 3).  357 
Differentially regulated pathways are visualized in Fig. 6A+B (p<0.01) and tabulated in 358 
Suppl. Table 4. In NNT KD siRNA cells, significant changes were observed in crucial pathways 359 
affecting cellular proliferation and viability (p53 pathway, MAPK pathway, checkpoint kinases). 360 
Interestingly, in KD shRNA cells one of the borderline significantly altered pathways (p<0.01, 361 
q=0.11) controlled protein processing in the ER, with up-regulation of genes encoding heat shock 362 
proteins (predominantly in the HSP40 family), chaperone proteins that facilitate correct protein 363 
folding and transfer of misfolded proteins to proteasomes for degradation (Suppl. Table 4) (17, 364 
18). Other significantly up-regulated pathways with stable NNT KD included ribosomal genes 365 
(p<0.01, q<0.05) and pyrimidine metabolism (p<0.01, q=0.11), including an up-regulation of RNA 366 
II polymerases. Taken together, these findings hint at a higher protein turnover which may allow 367 
cells to swiftly replace proteins that have sustained irreversible oxidative damage.  368 
Of note, recent rodent-based work by Meimaridou et al. performed RNA sequencing on 369 
mouse adrenal glands derived from three different mouse strains: a strain which carries an 370 
inactivating mutation of Nnt (C57BL/6J), a strain with wild-type Nnt expression (C57BL/6N), and 371 
transgenic mice overexpressing Nnt on the background of the NNT-deficient mouse strain (rescue 372 
 18 
model; C57BL/6JBAC) (16). We have extended this work here, carrying out additional, pathway 373 
analysis on this data. Detailed information on significantly dysregulated pathways in C57BL/6J vs 374 
C57BL/6N mice and C57BL/6J vs C57BL/6JBAC mice are presented in Suppl. Table 5. Significant 375 
dysregulation of the major cell signaling pathway of mitogen activated signaling kinases (MAPK) 376 
was one of the salient molecular changes in both comparisons; the same pathway was also 377 
dysregulated with transient NNT knockdown in NCI-H295R cells. Oxidative phosphorylation was 378 
up-regulated in both comparisons, but changes were much more pronounced in the C57BL/6J vs 379 
C57BL/6N comparison and likely to reflect a strain, rather than gene, effect.  380 
 RNA sequencing in NCI-H295R cells was complemented by whole metabolome analysis 381 
performed separately in cells and corresponding cell culture supernatant. In the siRNA knockdown 382 
model, NNT silencing was associated with a significant metabolic perturbation when compared to 383 
the SCR siRNA cells. An increase in the presence of 44 oxidized fatty acids supports a shift to a 384 
more oxidized intracellular microenvironment (Fig. 6C and Suppl. Tables 6 and 7). This was not 385 
observed in the stable NNT knockdown model. Pathway enrichment analysis demonstrated that 386 
six important metabolic pathways were enriched (q<0.05): tricarboxylic acid (TCA) cycle, 387 
arginine and proline metabolism, pyrimidine metabolism, nicotinate and nicotinamide metabolism 388 
and glutathione metabolism. Additional to this, we observed statistically significant changes 389 
(q<0.01) for 16 acyl carnitines, 25 fatty acids, 15 acyl amino acids, 20 purine and pyrimidine 390 
metabolites and 5 metabolites present in the nicotinate and nicotinamide metabolic pathway. Taken 391 
together, these indicate a perturbation in mitochondrial fatty acid beta-oxidation (as shown by 392 
changes in fatty acids, acyl carnitines and TCA metabolites), changes in nucleotide synthesis and 393 
a potential overload of acetyl units.  394 
In the stable NNT shRNA knockdown model, pathway enrichment analysis highlighted 395 
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changes in purine metabolism (q<0.05) and NNT knockdown cells exhibited a significant (p<0.05) 396 
rise in several purine and pyrimidine metabolites (Fig. 6D and Suppl. Tables 6 and 7), mirroring 397 
the results of the transcriptome analysis. Polyamine (spermine, spermidine) metabolism was also 398 
significantly modified in both models: KD siRNA cells displayed a dramatic increase in polyamine 399 
catabolism (accumulation of diacetyl-spermine, diacetyl-spermidine, spermine dialdehyde) 400 
leading to  depletion of spermine and spermidine, a response that has been associated with arrest 401 
of cell growth (Suppl. Tables 6 and 7) (19). Conversely, KD shRNA cells exhibited a significant 402 
rise in spermine, a polyamine that can act as a ROS scavenger (20, 21).   403 
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Discussion 404 
With this work, we have explored the immediate and longer-term impact of NNT silencing 405 
on ACC cells with respect to redox balance, mitochondrial bioenergetics, cell proliferation and 406 
viability, and steroidogenesis, using two distinct in vitro knockdown models in the human 407 
adrenocortical carcinoma cell line NCI-H295R. Our aim was to establish whether NNT inhibition 408 
can have therapeutically beneficial effects with respect to control of tumor growth and steroid 409 
excess. We hypothesized that NNT inhibition would compromise the ability of adrenocortical 410 
mitochondria to deal with oxidative stress, leading to progressive accumulation of ROS. ROS 411 
excess has multiple toxic sequelae, and can directly impair cell viability triggering apoptosis (8, 412 
12). Importantly, the adrenal-specific clinical phenotype in humans and the reported increased rate 413 
of adrenocortical cell apoptosis in otherwise healthy NNT mutant mice suggest that this 414 
manipulation may selectively target ACC cells, sparing other organs. This susceptibility of 415 
adrenocortical cells to mitochondrial antioxidant pathway disruption can be explained by the fact 416 
that enzymes involved in the rapid adrenal steroid response to stress represent a major additional 417 
source of ROS in the adrenals, increasing their dependence on efficient ROS scavenging (10, 11). 418 
In keeping with our hypothesis, we found that in the acute setting (siRNA-mediated 419 
transient knockdown), NNT loss increased intracellular oxidative stress. Redox balance 420 
perturbations in response to NNT loss have been previously demonstrated in a limited number of 421 
cell lines in vitro, as well as in lymphocytes derived from NNT mutant patients ex vivo (4, 22-25). 422 
These findings are in line with the biological role of NNT as a major mitochondrial generator of 423 
NADPH, the essential provider of reducing equivalents to the two main antioxidant pathways (26).  424 
Importantly, in our study we observed that NNT silencing led to an immediate and marked 425 
inhibition of cell proliferation accompanied by increased apoptotic rates. This anti-tumor effect 426 
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was even more pronounced when using a second anti-NNT siRNA (KD siRNA2). This apparent 427 
difference in degree (but not in direction) of cell response raised the possibility of additional, off-428 
target effects triggered by KD siRNA2; on interrogation of the NCBI Basic Local Assignment 429 
Search tool, however, neither of the two siRNAs share substantial homology with any genes that 430 
would be expected to impact cell proliferation and viability.  The association between excessive 431 
oxidative stress and mitochondrial apoptosis has been well established in the literature (8, 12), but 432 
data on the effects of NNT loss on cellular proliferation and viability are limited. Transient NNT 433 
silencing was previously shown to increase rates of apoptosis in PC12 (rat pheochromocytoma) 434 
cells (22); stable NNT knockdown in human melanoma cells was associated with reduced viability 435 
and high apoptotic rates in vitro, as well as slower growth of melanoma xenografts in mice (27). 436 
Meimaridou et al reported high levels of apoptosis in the zona fasciculata of the adrenal cortex 437 
from NNT mutant mice, as well as NCI-H295R cells stably transfected with shRNA against NNT 438 
in vitro (4). Although ROS have typically been associated with a stimulation of cellular 439 
proliferation, a number of in vitro models have demonstrated the opposite effect (suppression of 440 
cell division), in a complex relationship that may depend on the magnitude of ROS excess and/or 441 
tissue type (28, 29). NNT inhibition may also interfere with cellular proliferation in a ROS-442 
independent way, curtailing the amount of NADPH available to fuel the pressing anabolic needs 443 
of malignant cells. In keeping with the major impact on cellular viability and proliferation, we 444 
observed far-reaching metabolic effects of NNT knockdown implicating several areas of cell 445 
metabolism, including mitochondrial fatty acid oxidation, polyamine metabolism and nucleotide 446 
synthesis. The enhanced cellular sensitivity to oxidative stress in the aftermath of NNT silencing 447 
(paraquat treatment) is translationally important, as oxidative stress is induced by a number of 448 
classic chemotherapy agents, contributing to their cytotoxic effect (8, 30). NNT inhibition could 449 
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represent a feasible strategy to sensitize ACC to such drugs 450 
The longer-term effects of NNT loss on ACC cells, as delineated in the stable knockdown 451 
model, were disparate from the ones encountered in the acute setting. Importantly, with long-term 452 
culture under constant NNT silencing, NCI-H295R ACC cells managed to restore their redox 453 
balance. This compensation abrogated the pro-apoptotic early impact of NNT loss. Interestingly, 454 
a persistent proliferative handicap was demonstrated, though this was less marked than the one 455 
observed in the acute setting. This may be attributable to the limited supply of NADPH in the 456 
absence of NNT. Extracellular flux analysis revealed higher rates of oxygen consumption in KD 457 
shRNA cells, a response that may reflect higher energy needs or be driven by the spare NADH 458 
which fails to be converted to NADPH in NNT-deficient cells. Previous studies on the effect of 459 
NNT silencing on oxygen consumption have shown mixed results, which may be cell type-460 
dependent (22, 25, 31).  461 
Redox adaptation to oxidative stress has been previously described in tumor models in 462 
vitro; this process is driven by the strong selective pressure applied by oxidative toxicity and 463 
promoted by the genomic instability which characterizes the oxidized intracellular 464 
microenvironment (32). We obtained insights into how this adaptation was facilitated in our model 465 
by comprehensive transcriptome and metabolome analysis. In NNT KD shRNA cells, we observed 466 
an up-regulation of genes that are involved in protein folding in the ER, as well as in the 467 
identification and degradation of damaged proteins. Purine and pyrimidine metabolism was 468 
activated in these cells, and ribosomal genes were up-regulated. Taken together, these findings 469 
hint at increased protein turnover, involving degradation of damaged protein and acceleration of 470 
new protein synthesis. This may represent a key compensatory mechanism against oxidative stress, 471 
achieving the timely removal and replacement of irrevocably damaged (oxidized) proteins. The 472 
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observed increase in oxygen consumption could provide additional energy to fuel this process. Of 473 
note, we recently described up-regulation of chaperone proteins in the adrenals of NNT-deficient 474 
mice (16). The additional pathway analysis we performed on the same RNA sequencing data from 475 
that rodent work displayed otherwise limited overlap with our in vitro model, likely reflecting the 476 
expected biological differences between a healthy mouse adrenal and a malignant human adrenal 477 
cell line.  478 
Interestingly, polyamine metabolism exhibited dramatic shifts in opposite directions in the 479 
two models. Polyamines (spermine, spermidine) are versatile cationic molecules involved in a 480 
number of cell processes, including ROS scavenging and cell proliferation (19, 33).  High 481 
endogenous polyamine levels have been found in a number of cancer types (34). Acute NNT loss 482 
was accompanied by a rapid accumulation of acetylated catabolic products of polyamines, leading 483 
to depletion of spermine and spermidine. Polyamine catabolism can both be triggered by oxidative 484 
stress and generate hydrogen peroxide (H2O2), creating a vicious cycle that propagates ROS 485 
accumulation (33, 35). Indeed, stimulated polyamine catabolism has been associated with growth 486 
arrest and cell death in various in vitro models (19, 36). Conversely, in the chronic setting, stable 487 
NNT knockdown cells demonstrated increased spermine concentrations and no evidence of 488 
accelerated polyamine catabolism. This response is likely to represent a major facilitator of the 489 
successful redox adaptation in this model. Our findings underscore the importance of polyamine 490 
homeostasis in adrenocortical carcinoma cells. 491 
Within the same framework, we also explored alternative antioxidant targets focusing on 492 
the glutathione and thioredoxin pathways.  Pertinently, human mutations in thioredoxin reductase 493 
2 have also been shown to result in isolated glucocorticoid deficiency (37). We used BSO to inhibit 494 
glutathione synthesis. BSO has shown anti-proliferative effects against a number of cell lines in 495 
 24 
vitro (38-43). We  observed a significant suppression of cell growth with doses of 100 M, i.e. 496 
at doses that are clinically attainable in plasma with no serious toxicity (38). Auranofin, a gold 497 
complex-based agent able to inhibit thioredoxin reductase, also suppressed cell proliferation at 498 
doses 1M and was associated with marked cytotoxicity at doses of  2 M. Auranofin has also 499 
displayed anti-tumor activity against a number of cell lines in vitro and is currently being 500 
investigated in clinical trials against leukemia (44-47). Applying combined treatment with low 501 
doses of both agents, we observed a dramatic cytotoxic impact, suggesting that dual antioxidant 502 
targeting can achieve potent synergistic results. 503 
The observed effects of NNT silencing on NCI-H295R steroidogenesis were surprising. In 504 
the acute setting, i.e. NNT siRNA knockdown, we observed a generalized stimulation of 505 
steroidogenesis, leading to increased glucocorticoid and adrenal androgen output by the cells. This 506 
was corroborated by a significant up-regulation of a number of steroidogenic enzymes. This 507 
response is contrary to what one might have anticipated considering mitochondrial NADPH is an 508 
essential cofactor to the steroidogenic cytochrome P450 enzymes CYP11A1, CYP11B1 and 509 
CYP11B2.  Elucidating the mechanisms that drive this transient effect will require additional 510 
studies.  The few studies exploring the relationship between ROS and steroidogenesis (mostly on 511 
testicular Leydig cell tumor cells) have reported a down-regulation of steroidogenic enzymes with 512 
oxidative stress (14, 48-50). Human patients with inactivating NNT mutations (4)   and a murine 513 
Nnt deletion model (16)   has been shown to have disrupted steroidogenesis; the data from our in 514 
vitro NNT knockdown models suggest that NNT loss is not limiting for adrenal steroidogenesis.  515 
Interestingly, Zhao et al. demonstrated a biphasic relationship between ROS and steroidogenesis, 516 
indicating that the direction of the effect is dose-dependent (51) .  517 
Taken together, we show that NNT silencing can induce cytotoxicity and impede cell 518 
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growth in adrenocortical carcinoma cells, as well as sensitize them to chemically-induced 519 
oxidative stress. Moreover, we have demonstrated how the plasticity of ACC cells can lead to the 520 
development of a compensatory molecular response with time and described how changes in 521 
polyamine metabolism and ER protein processing are involved in this process (Fig. 7). A limitation 522 
of our work is that it is based on a single cell line; however, NCI-H295R remains the only 523 
established, well characterized steroidogenic human ACC cell line.  These results merit further 524 
exploration with in vivo studies to corroborate the effectiveness of mitochondrial anti-oxidant 525 
pathway targeting and explore its durability, alone or in combination with other pro-oxidant agents. 526 
The unique features of adrenocortical cells, with their high-volume ROS generation due to 527 
steroidogenesis, make ACC a most amenable target to this approach. 528 
 529 
 530 
 531 
  532 
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Figures 680 
Fig. 1: A, Interaction between NNT and the mitochondrial antioxidant pathways. ETC: electron 681 
transfer chain; ATP: adenosine triphosphate; GSR: glutathione reductase; GSSG: oxidized 682 
glutathione; GSH: reduced glutathione; GPX1: Glutathione peroxidase 1; TXNRD2: thioredoxin 683 
reductase 2; TXN: oxidized thioredoxin; TXN-SH: reduced thioredoxin; GPX3: peroxiredoxin 3; 684 
O2.-: superoxide; H2O2: hydrogen peroxide, SOD2: Superoxide dismutase 2. B, NNT expression 685 
in patients with ACC (n=33), compared to patients with adrenocortical adenomas (n=22) and 686 
healthy adrenals (n=10). Gene expression was quantile-normalized and log-transformed as 687 
described (13); bars represent median and interquartile range (IQR). Gene expression across 688 
groups was compared applying the Kruskall-Wallis test, followed by post-hoc Bonferroni test. 689 
**p<0.01.             690 
 691 
Fig. 2: Effects of transient (siRNA-mediated) NNT silencing on NCI-H295R cell redox balance, 692 
respiration, proliferation and viability. Bars represent mean  SEM values, unless otherwise 693 
stated.  A, GSH/GSSG ratio in NCI-H295R cells transfected with KD siRNA (96 hours post-694 
transfection), normalized to the corresponding ratio of SCR siRNA-transfected cells. Significant 695 
suppression of the GSH/GSSG ratio in KD siRNA cells suggests higher intracellular oxidative 696 
stress. Bars represent median  IQR values. *p<0.05; n=8 independent experiments. B, 697 
Proliferation rates observed in siRNA-transfected NCI-H295R cells, 72-166 hours post-698 
transfection. ***p<0.001; n=14. C, Caspase 3/7 activity ratio in KD siRNA cells to SCR siRNA-699 
transfected cells, after standardization to cell numbers (120 hours post-transfection). *p<0.05; 700 
n=8. D, Seahorse XF24 analysis of cellular oxygen consumption rate (OCR) at baseline and after 701 
successive application of three mitochondrial respiration inhibitors (166 hours post-transfection). 702 
Results were standardized to protein concentration. Bars represent median  IQR values. FCCP: 703 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone. A-mycin/Rot: Antimycin A plus Rotenone. 704 
p>0.05; n=4. E, Extracellular acidification rate (ECAR), surrogate marker of anaerobic 705 
glycolysis, standardized for protein concentration. p>0.05; n=4. F, Proliferation under low-dose 706 
chemically induced oxidative stress (paraquat 10 μM) in KD siRNA and SCR siRNA-transfected 707 
cells, normalized to corresponding cell proliferation without paraquat treatment. *p<0.05; n=6.  708 
 709 
Fig. 3: Effects of stable (shRNA-mediated) NNT silencing on NCI-H295R cell redox balance, 710 
respiration, proliferation and viability. Bars represent mean  SEM values, unless otherwise 711 
stated. A, GSH/GSSG ratio in NCI-H295R cells transfected with KD shRNA, normalized to the 712 
corresponding ratio cells transfected with SCR shRNA. Bars represent median  IQR values. 713 
p>0.05, n=10. B, Proliferation rates over a 96-hour period. *p<0.05; n=13.  C, Caspase 3/7 714 
activity ratio in KD shRNA cells to SCR shRNA-transfected cells, after standardization to cell 715 
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numbers. p>0.05; n=4. D, Seahorse XF24 analysis of cellular oxygen consumption rate (OCR) at 716 
baseline and after successive application of three mitochondrial respiration inhibitors. Results 717 
were standardized to protein concentration. Bars represent median  IQR values. FCCP: 718 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone. A-mycin/Rot: Antimycin A plus Rotenone. 719 
*p<0.05; n=7.  E, Extracellular acidification rate (ECAR) standardized for protein concentration. 720 
p>0.05; n=7. F, Proliferation under chemically induced oxidative stress (paraquat) in KD shRNA 721 
and SCR shRNA cells, normalized to corresponding cell proliferation without paraquat treatment. 722 
p>0.05; n=13.  723 
 724 
Fig. 4: Effects of NNT silencing on NCI-H295R steroidogenesis, delineated by LC-MS/MS 725 
steroid profiling in serum-free cell media and RNA sequencing. Cortisol production (A) and 726 
androstenedione production (B) over a 48-hour period in NCI-H295R cells transfected with siRNA 727 
or shRNA. A significant stimulation of cortisol and androstenedione synthesis was observed 72-728 
120 hours post-transfection with KD siRNA. **p<0.01, *p<0.05; n5. C-E, specific enzyme 729 
activity derived from product to substrate ratios for 11β-hydroxylase (CYP11B1) (C), 21-730 
hydroxylase (CYP21A2) (D) and 17,20-lyase (CYP17A1) (E) in siRNA and  shRNA-transfected 731 
cells. **p<0.01, ***p<0.001; n5. F, Heat-map representation of steroidogenic gene expression 732 
changes induced by transient and stable NNT knockdown, as revealed by RNA sequencing. Scale 733 
represents log2fold changes in NNT knockdown cells compared to their respective (siRNA or 734 
shRNA) scrambled controls. *q<0.05, **q<0.01; n=3. 735 
 736 
Fig. 5: Effect of glutathione and thioredoxin pathway inhibition on NCI-H295R cell 737 
proliferation. A, 96-hour treatment with incremental doses of BSO (0-200 μM), inhibitor of 738 
glutathione synthesis. Control cells were treated with vehicle only. *p<0.05, n=9. B, 96-hour 739 
treatment with incremental doses of auranofin (0-5 μM), a thioredoxin reductase inhibitor. Control 740 
cells were treated with vehicle only. Negative proliferation rates indicate net decrease in cell 741 
number after 96 hours of treatment. **p<0.01, ****p<0.0001; n=9. C, Combined glutathione and 742 
thioredoxin inhibition by use of low-dose BSO (50 M) and auranofin (0.2 M). *p<0.05; n=3. 743 
 744 
Fig. 6: Whole transcriptome sequencing and non-targeted metabolome analysis of KD siRNA, 745 
SCR siRNA, KD shRNA and SCR shRNA-transfected NCI-H295R cells. A+B, Whole 746 
transcriptome sequencing in siRNA and shRNA-transfected NCI-H295R cells. A, Significantly 747 
altered molecular pathways (p<0.01, q<0.05) between KD siRNA and SCR siRNA cells and 748 
number of associated genes that are up/down-regulated in KD siRNA cells. B, Significantly altered 749 
molecular pathways (p<0.01) between KD shRNA and SCR shRNA cells and number of associated 750 
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genes that are up/down-regulated in KD shRNA cells. C+D, Non-targeted metabolome analysis in 751 
siRNA and shRNA-transfected NCI-H295R cells. C, Significantly up- and down-regulated 752 
intracellular metabolites (q<0.01) in KD siRNA-transfected cells, as compared to SCR siRNA-753 
transfected cells. D, Significantly up- and down-regulated intracellular metabolites (p<0.05) in 754 
KD shRNA-transfected cells, as compared to SCR shRNA-transfected cells (no metabolites with 755 
q<0.05 in this comparison).  756 
 757 
Fig. 7: Response of NCI-H295R cells to NNT silencing in the acute (transient knockdown) and 758 
chronic (stable knockdown) setting, with proposed redox adaptation mechanisms. Acute NNT 759 
knockdown induces oxidative stress as predicted by NNT’s role as a major NADPH generator; 760 
enhanced steroidogenesis and polyamine catabolism further accentuate ROS accumulation, 761 
triggering apoptosis and a sharp decline in cell proliferation. With time (stable knockdown), cells 762 
manage to adapt removing damaged proteins and enhancing spermine synthesis as an alternative, 763 
NADPH-independent ROS scavenger. This restores redox homeostasis and abrogates the original 764 
pro-apoptotic effect, but cellular proliferation remains suppressed. Horizontal arrows represent 765 
paucity of change.  766 
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